“…The later stages include cone dysfunction, including constricted visual fields, loss of central vision, and reduced light‐adapted ERG responses. RP has extreme locus heterogeneity, with >90 genes associated with the nonsyndromic form, and is associated with hundreds of syndromic disorders, including ciliopathies, peroxisomal disorders, and multiple (>500) malformation syndromes (Hartong et al, 2006; Schneider et al, 2021; Verbakel et al, 2018). Recently, a Food and Drug Administration‐approved gene‐directed therapy, the first in its class, has emerged for early‐onset retinal degeneration caused by variants in the RPE65 gene (MIM# 180069).…”